10-Q quarterly report · filed Nov 5, 2026

Alector, Inc. (ALEC) Q3 2026 10-Q Quarterly Report

Short answer

Alector, Inc. (ALEC) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $163M (up 4895.9% year over year) with net income of $125M.

Q3 2026 key financials · XBRL

Revenue
$163M
+4895.9% YoY · +4805.6% QoQ
Net income
$125M
+459.4% YoY · +642.0% QoQ
Operating margin
76.0%
EPS (diluted)
$1.11
+426.5% YoY · +655.0% QoQ

Source: XBRL data from the Alector, Inc. (ALEC) Q3 2026 10-Q on SEC EDGAR. USD.

Alector, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Collaboration revenue $162.9M, up $159.6M YoY from $3.3M, driven by GSK deferred-revenue recognition
  • Net income $124.6M vs net loss $34.7M YoY, operating margin 76.0% vs negative 1,153.4%
  • AL137/AL037 R&D $3.5M, other programs $18.5M, strongest disclosed development spending
  • Cash, equivalents and marketable securities $138.7M; operating cash outflow $108.2M for nine months
  • Genentech $100.0M upfront and October offering $75.0M gross; funding expected into second half of 2029

Risk Factors

  • Newly added financing risk: October 2026 underwritten offering and Genentech upfront payment expected to extend cash runway into the second half of 2029
  • Most material update, regulatory operations: FDA staffing reductions and policy changes may delay submissions, inspections, and clinical development timelines
  • Clinical risk: GSK discontinued PROGRESS-AD in April 2026 after interim futility analysis found nivisnebart unlikely to meet its primary endpoint
  • Competitive risk: Approved Alzheimer’s therapies lecanemab and donanemab may hinder enrollment and intensify market competition
  • Financial concentration risk: Future Genentech revenue depends on AL050 milestones, royalties, and product sales that may never occur

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Alector, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.